Clinical Trial: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07849231) titled 'Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms' on Sept. 21.

Brief Summary: This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Myeloproliferative Neoplasms (MPNs)

Inte...